GlassScriptPhysician profile
Carmella N Imig
NPI 1194823302
$4,461.76
in general payments reported to CMS, 2019-2025
46 companies · $724 in 2025
The $724 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $712 · 2021: $884 · 2022: $552 · 2023: $627 · 2024: $729 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,079.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $683.77 | 2021-2025 | |
| Novo Nordisk INC | $547.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $536.97 | 2019-2025 | |
| Amgen INC. | $327.62 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $288.24 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $269.22 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $234.83 | 2019-2025 | Airsupra |
| Aimmune Therapeutics, INC. | $97.54 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.45 | 2020-2023 | |
| Upsher-Smith Laboratories LLC | $79.42 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.39 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $70.78 | 2022 | |
| Ibsa Pharma INC. | $70.55 | 2020-2022 | |
| Esperion Therapeutics, INC. | $69.15 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $68.62 | 2020-2025 | Vaxneuvance, M-M-R II, Gardasil 9 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmella Imig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.